therapeutics

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company…

8 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on…

9 months ago

Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS,…

9 months ago

Gain Therapeutics Announces Proposed Public Offering

July 15, 2025 16:36 ET  | Source: Gain Therapeutics, Inc. BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics,…

9 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing…

9 months ago

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

9 months ago

LENZ Therapeutics and Laboratoires Tha Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net…

9 months ago

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics…

9 months ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…

9 months ago

Akari Therapeutics Releases Virtual Investor What This Means Segment Highlighting its Recently Granted India Patent

June 25, 2025 09:00 ET  | Source: Akari Therapeutics Plc Access the “What This Means” segment here BOSTON and LONDON,…

9 months ago